Journal of Clinical and Cellular Immunology
Open Access
ISSN: 2155-9899
+44 1223 790975
ISSN: 2155-9899
+44 1223 790975
S Krupanidhi, G Vaishnav and C B Sanjeevi
Accepted Abstracts: J Clin Cell Immunol
The Epstein-Barr virus (EBV)-encoded latent membrane protein 1 (LMP1) is a key effector of EBV-mediated B cell transformation. LMP1 displays oncogenic properties in fibroblasts, and induces a wide range of effects in B cells and a variety of growth-promoting effects in human epithelial cells. The constitutive activation of these signaling cascades explains LMP1's ability to induce morphological and phenotypic effects in cells. Taken as a whole, these findings demonstrate that LMP1 can induce profound effects in epithelial cells, many of which may account for its oncogenic properties. There is now strong evidence supporting a role of EBV encoded LMP-1 protein in the pathogenesis of nasopharyngeal carcinoma (NPC), but also, there are other molecular pathology variables which can predict clinical outcome in these patients. Accordingly, we aimed to systematically analyze LMP1 immunoexpression in patients with non-endemic NPC and do a correlation with clinicopathological features and patients survivals. Our data suggest that LMP1 expression could be correlated with a poorer clinical outcome and prognosis in patients with NPC. To our knowledge, this series is the first one published in non- endemic/non-white population of NPC; and supports the importance to explore the molecular signaling pathways to provide a substantial opportunity for identification of novel diagnostic and prognostic biomarkers that could improve individual treatment in patients with NPC.